ModifiedPremera BluecrossPolicy N/A

Xolair (omalizumab) — coverage and site‑of‑service criteria

Medical necessity and site-of-service coverage criteria for Xolair (omalizumab) for asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and select IgE-mediated conditions; includes documentation, coding, age and benefit application notes affecting Premera members.

Policy Summary

PayerPremera Bluecross

PolicyXolair (omalizumab) — coverage and site‑of‑service criteria

Policy CodePolicy N/A

Change TypeCriteria revisions and added indications

Effective DateFeb. 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization showing maximum tolerated inhaled corticosteroid plus controller therapy and required documentation of severity or exacerbation history.

SourceLink

POLICY UPDATE CHANGES

Updated asthma criteria to remove adult smoking exclusion and revised diagnostic/exacerbation criteria effective January 3, 2025.

Added that omalizumab is not to be used in combination with tezepelumab for asthma and not to be used in combination with dupilumab for nasal polyps.

Included treatment of certain individuals with IgE-mediated food allergies in the policy criteria.

Changed asthma criteria to require maximum tolerated doses of inhaled corticosteroid rather than maximum doses.

Updated initial approval length for Xolair for chronic idiopathic urticaria (CIU) to 6 months.

Clarified that medications in the policy are subject to their FDA dosing and administration information and non-formulary exception authorizations may be approved up to 12 months.

J2357HCPCS code for omalizumab

40-50%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Moderate to severe persistent asthma

Covered when ALL of the following are met for moderate to severe persistent allergic asthma:

Asthma initial criteria: Individual is aged 6 years or older; positive skin test or in vitro reactivity to a perennial aeroallergen; using maximum tolerated inhaled corticosteroid AND using an inhaled long-acting beta-agonist (LABA); meets at least one of: two or more asthma exacerbations in the previous 12 months requiring oral corticosteroids OR one or more asthma exacerbations in the previous 12 months requiring hospitalization, emergency department, or urgent care OR FEV1 <80% predicted OR FEV1/FVC <0.80 OR asthma that worsens upon tapering of oral corticosteroid therapy; total serum IgE within age-specified ranges (30–1300 IU/mL for ages 6–12 OR 30–700 IU/mL for age ≥12); weight between 20 kg and 150 kg; prescribed dose limited to 750 mg every 4 weeks per manufacturer's dosing table; not used in combination with dupilumab, reslizumab, tezepelumab (when used for asthma); prescribed by or in consultation with an allergist/immunologist or pulmonologist.

Severe chronic idiopathic urticaria

Covered when ALL of the following are met for severe chronic idiopathic urticaria:

Urticaria criteria: Individual is aged 12 years or older; no evidence of another cause of the urticarial reaction; symptoms for at least 6 weeks (chronic urticaria, itching, hives, or angioedema); failed or intolerant to at least 2 H1-antihistamines at high doses (at least twice normal up to 4× or maximum tolerated dose); plans to continue low‑dose H1 antihistamines while on therapy; omalizumab is not used in combination with dupilumab or remibrutinib for urticaria; prescribed dose is 150 mg or 300 mg every 4 weeks; prescribed by or in consultation with an allergist/immunologist.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Covered when ALL of the following are met for CRSwNP:

CRSwNP criteria: Individual is aged 18 years or older; has at least 2 of: facial pressure or pain, moderate–severe nasal congestion/discharge/obstruction, or significant loss of smell; pretreatment total serum IgE ≥30 IU/mL; weight between 30 kg and 150 kg; diagnosis of inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy; inadequate response or intolerance to intranasal corticosteroid monotherapy and omalizumab is prescribed in combination with an intranasal corticosteroid; and one of: prior systemic corticosteroids for polyps in the last 2 years OR contraindication to systemic corticosteroids OR prior bilateral nasal polyp surgery; dosing limited to 600 mg every 2 weeks per prescribing information dosing table; prescribed by or in consultation with an allergist/immunologist or pulmonologist/ENT as appropriate.

Immunoglobulin (Ig)E-mediated food allergy

Covered when ALL of the following are met for IgE-mediated food allergy (as stated):

IgE-mediated food allergy: Medication is prescribed by or in consultation with an allergist/immunologist or otolaryngologist (ENT); dosing follows the most recent prescribing information dosing table; use is considered in the context of available trial data (e.g., the NIAID-sponsored OUtMATCH trial) and per policy operational guidance for food-allergy indications.

Asthma (maintenance) — contextual criteria

Covered when used as add-on therapy for individuals with moderate to severe persistent allergic asthma inadequately controlled with standard therapy.

Asthma add-on criteria: 1) Individual has moderate to severe persistent asthma. 2) Inadequate control despite optimized therapy, including use of maximum tolerated dose of inhaled corticosteroid plus other controllers as appropriate (e.g., LABA). 3) Evidence of allergic sensitization (positive skin test or in‑vitro reactivity to a perennial aeroallergen). 4) Dosing determined by body weight and total serum IgE per product labeling and dosing table.

Derived from maintenance therapy rationale and explicit dosing/IgE/weight requirements in policy.

Chronic Idiopathic Urticaria (CIU)

Covered when used for CIU not controlled with antihistamines at approved doses consistent with trial inclusion criteria.

CIU trial-based criteria: 1) Chronic idiopathic urticaria refractory to H1 antihistamine therapy with symptom duration ≥6 weeks. 2) Severity comparable to clinical trials (e.g., UAS7 ≥16 and weekly itch severity ≥8 prior to treatment). 3) Failed or intolerant to at least 2 H1‑antihistamines at high or maximum tolerated doses. 4) Preferred effective doses are 150 mg or 300 mg every 4 weeks (75 mg did not consistently demonstrate efficacy).

Based on CIU pivotal trials described in the evidence review.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Covered when used for CRSwNP inadequately responsive to intranasal corticosteroids consistent with trial criteria.

Nasal polyps trial-based criteria: 1) Bilateral CRSwNP inadequately controlled on intranasal corticosteroid therapy. 2) Baseline nasal polyp score (NPS) consistent with trials (e.g., NPS ≥5 with ≥2 in each nostril) and weekly average nasal congestion score >1 despite nasal corticosteroid. 3) Background intranasal corticosteroid continued while on omalizumab. 4) Dosing and eligibility consistent with pretreatment IgE and weight per prescribing information and dosing table.

Derived from CRSwNP trial inclusion criteria and policy requirements.

Food allergy (investigational/limited evidence)

Not established routine coverage — evidence from an NIAID-sponsored trial in multi-food allergic individuals is preliminary.

Food allergy context: 1) The OUtMATCH trial evaluated omalizumab in individuals allergic to peanut plus ≥2 other foods; 2) Efficacy evidence includes pediatric data and an open‑label extension but uncontrolled OLE data do not establish routine adult effectiveness; 3) Policy currently considers this an emerging indication and may treat routine coverage as investigational pending further evidence and operational criteria.

Summarizes trial context and policy stance on routine coverage.

Asthma (Initial Therapy) Coverage Criteria

Covered for moderate-to-severe persistent allergic asthma when ALL applicable criteria are met (updated criteria):

Asthma indication general: Individual meets the FDA‑labeled indication for moderate‑to‑severe persistent allergic asthma and dosing follows FDA prescribing information and manufacturer's dosing table.

Exacerbation or severity criteria: Individual has either: (A) two or more asthma exacerbations in the prior 12 months requiring oral corticosteroids; OR (B) one or more exacerbations in the prior 12 months requiring hospitalization, emergency department, or urgent care; OR (C) FEV1 <80% predicted; OR (D) dependence on oral corticosteroids or asthma that worsens upon tapering of oral corticosteroids.

Therapy optimization: Individual has been treated with maximum tolerated dose of inhaled corticosteroid plus appropriate controllers (e.g., LABA) and remains inadequately controlled despite optimized therapy.

Combination therapy exclusion:

CIU/CSU (Initial Therapy) Coverage Criteria

Covered for CIU/CSU in individuals 12 years and older when ALL of the following are met:

Age and diagnosis: Individual is 12 years or older with chronic idiopathic/spontaneous urticaria refractory to H1‑antihistamine therapy.

Prior therapy: Failure of high‑dose H1‑antihistamine therapy (up‑to 4× dosing) or intolerance/contraindication to such therapy; plan to continue a low dose of H1 antihistamine while on omalizumab.

Trial and authorization length: Initial authorization may be up to 6 months; ongoing response must be documented for continuation per policy re‑authorization requirements.

Dosing response: Dosing may be 150 mg or 300 mg every 4 weeks; 300 mg demonstrated greater efficacy in trials though higher serious adverse events were observed at the highest dose group in some studies; 75 mg did not consistently demonstrate efficacy.

CRSwNP Coverage Criteria

Covered for inadequately controlled bilateral CRSwNP when ALL of the following are met:

Diagnostic confirmation: Diagnosis of bilateral CRSwNP confirmed by physical examination, sinus CT, or nasal endoscopy.

Symptom criteria: Individual has at least 2 of: facial pressure/pain, moderate‑to‑severe nasal congestion/drainage/obstruction, or significant loss of smell.

Prior interventions: One of: prior systemic corticosteroids to treat nasal polyps in the last 2 years OR contraindication to systemic corticosteroids OR prior surgical removal of bilateral nasal polyps.

Combination therapy exclusion: Omalizumab must not be used in combination with dupilumab for nasal polyps.

Dosing and Dose Adjustment Criteria

Dosing and dose‑adjustment rules and CIU dosing

Asthma dosing tables: Dosing frequency and dose bands for asthma are determined every 2 weeks per manufacturer tables that map total serum IgE and body weight to mg doses; some weight/IgE combinations are marked 'DO NOT DOSE' where dosing is not provided.

IgE testing and dose adjustments: Total serum IgE rises during treatment and may remain elevated up to one year after stopping; re‑testing during active treatment is not useful for dose determination. Dose determination after interruptions <1 year should use initial IgE; re‑test only if treatment interrupted ≥1 year. Adjust doses for significant changes in body weight.>=1 year

CIU dosing: For chronic idiopathic urticaria, administer omalizumab 150 mg or 300 mg subcutaneously every 4 weeks. CIU dosing is independent of serum IgE and body weight; periodically reassess need for continued therapy.every 4 weeks

Xolair (omalizumab) is considered investigational for all other uses not listed in this policy. Examples include, but are not limited to: allergic rhinitis, atopic dermatitis, other IgE‑mediated allergic conditions not specified in this document, latex allergy, bullous pemphigoid, and eosinophilic gastrointestinal disorders.

In randomized CIU trials, Xolair 150 mg and 300 mg produced greater reductions in itch and hive scores compared with placebo; however, the 75‑mg dose did not demonstrate consistent evidence of efficacy and is not approved for use for chronic idiopathic urticaria.

The policy prohibits concurrent use of omalizumab with certain biologic therapies: do not use omalizumab in combination with tezepelumab for asthma, and do not use omalizumab in combination with dupilumab for nasal polyps. Combination use will trigger denial under the updated criteria.

The manufacturer's every‑2‑weeks dosing tables include entries labeled "DO NOT DOSE" for specific body weight and total serum IgE combinations; these table entries indicate that dosing is not provided or recommended for those combinations and should not be used to determine a regimen.

Additional dosing-table entries for the every‑2‑weeks administration schedule contain blank cells or explicit "DO NOT DOSE" markings for certain weight/IgE combinations; when a table cell is marked this way, do not dose for that combination.

Omalizumab use is not recommended for populations who have not demonstrated inadequate control despite optimized, maximal tolerated therapy (for example, inhaled corticosteroids plus appropriate controllers in asthma). The policy also notes concerns about cost‑effectiveness and positions omalizumab as a last‑line add‑on option rather than broad use.

Multiple literature and prescribing‑information reviews across annual updates were performed and the reviewers reported no new evidence prompting a change in policy in several review years; the policy history documents repeated literature reviews and incremental updates rather than evidence requiring wholesale change.

Because total serum IgE levels remain elevated during treatment and for up to one year after stopping, re‑testing IgE during active Xolair therapy is not useful for dose determination and therefore should not be used to guide dose changes. Serum IgE may be re‑tested only if treatment has been interrupted for ≥ 1 year.

Coding

HCPCS codesHCPCS

J2357

Injection, omalizumab (Xolair), 5 mg

Covered HCPCS Codes (referenced historically)HCPCSCovered

J2357

Omalizumab injection

Weight and IgE dosing thresholds

Weight range — asthma20–150 kg (44–330 lbs.)

Weight range — CRSwNP30–150 kg (66–330 lbs.)

Total serum IgE — ages 6–1230–1,300 IU/mL

Total serum IgE — ages ≥1230–700 IU/mL

Maximum listed dose (q4w)Limited to 750 mg every 4 weeks per manufacturer dosing table

Asthma exacerbation and lung function thresholds

Asthma exacerbations — oral corticosteroids

Provider Actions and Authorization

Prior Authorization

Authorization and Approval Lengths

Prior Authorization Required. Prior authorization is required for Xolair (omalizumab) and site-of-service medical necessity review may apply for injectable administration. Initial authorizations (except non-formulary exceptions) are typically approved up to 6 months; non-formulary exception reviews may be approved up to 12 months. Re-authorization for moderate to severe persistent asthma may be approved up to 12 months when medical necessity and continued clinical response are documented. Re-authorization for severe CIU and CRSwNP may be approved up to 12 months when continued clinical response is documented.

Initial approval length for CIU clarified to 6 months (2023 update).
Non-formulary exception reviews for all drugs may be approved up to 12 months.
Re-authorization approvals may be granted up to 12 months for asthma, CIU, and CRSwNP when criteria and documented response are met.

Step Therapy

Prior Authorization for Asthma — Step Therapy Context

Omalizumab is positioned as an add-on/step option after optimized inhaled corticosteroid and controller therapy per asthma maintenance guidance. Prior therapies must include use of maximum tolerated inhaled corticosteroid and a LABA, with additional controllers (e.g., leukotriene modifiers, theophylline) as clinically indicated.

Background and Evidence Summary

Xolair (omalizumab) is a recombinant humanized monoclonal antibody that binds circulating IgE, preventing IgE binding to high‑affinity FcεRI receptors on mast cells and basophils. It is used as an add‑on therapy for moderate to severe allergic asthma and for certain other IgE‑mediated conditions such as chronic spontaneous/idiopathic urticaria and chronic rhinosinusitis with nasal polyps when criteria are met.

Definitions

Site of service

Physician's officeAdministration in a physician's office is a medically necessary site of service

Infusion centerOutpatient infusion center is an approved site of service

Home infusionHome infusion (IV infusion/injection) may be covered when appropriate and available

Hospital-based outpatient settingHospital-based outpatient infusion department is medically necessary for initial courses or re-initiation after ≥6 months or when no other safe option exists

Nasal Congestion Score (NCS)

NCS scale range0–3

Revision History

2026-01-13interim_reviewLatest

Interim review approved; updated criteria for the treatment of indications (see history).

2025-10-03effective_date

Site of service review added and clarified that Site of Service Medical Necessity criteria can apply to injection drugs (changes effective following 90-day provider notification).

2025-04-01revision

Step Therapy

Treatment Sequencing and Step Therapy Requirements

Treatment sequencing requirements differ by indication. For CIU, omalizumab is indicated after failure of high‑dose H1‑antihistamines (at least two H1 antihistamines in high doses, up to 4x normal dosing) and continuation of low‑dose H1 antihistamines. For CRSwNP, prior use of systemic corticosteroids in the last 2 years, contraindication to systemic corticosteroids, or prior surgical removal of bilateral nasal polyps is required; diagnosis must be confirmed by exam, CT, or endoscopy. For asthma, omalizumab is reserved for individuals inadequately controlled despite inhaled corticosteroid + LABA and other controllers.

CIU: documented failure/intolerance to ≥2 H1 antihistamines at high doses (and symptom duration ≥6 weeks).
CRSwNP: inadequately controlled bilateral disease confirmed by exam, CT, or nasal endoscopy and prior systemic corticosteroid use or surgery.
Asthma: step-through of inhaled corticosteroid + LABA and meeting exacerbation/FEV1 or FEV1/FVC criteria.

Documentation Required

Prior Authorization — Dosing Reference and Documentation

Dosing reference and documentation requirements for prior authorization: dosing must follow the most recent manufacturer prescribing information and dosing tables. For asthma dosing, initial dose determination requires baseline total serum IgE and body weight per the manufacturer table; dosing for CIU is 150 mg or 300 mg every 4 weeks and does not depend on serum IgE or body weight. Re‑testing of total IgE during treatment is not used for routine dose changes; repeat IgE testing only after treatment interruption ≥1 year. Doses should be adjusted for significant weight changes.

Authorize based on most recent FDA prescribing information dosing tables.
Asthma: baseline total serum IgE and weight required to determine dose; follow manufacturer tables (do not dose outside recommended combinations).
CIU: fixed dosing 150 mg or 300 mg every 4 weeks; not weight/IgE dependent.
Re-testing IgE only if treatment interrupted ≥1 year; otherwise use initial IgE for dose determination after interruptions <1 year.

Documentation Required

Required Clinical and Baseline Severity Documentation

Required clinical documentation at time of request: office visit notes with diagnosis, relevant history, physical evaluation, medication history, and prior therapy trials. Baseline severity documentation is required per indication: asthma — documentation of exacerbation history, hospital/ED/urgent care visits, FEV1 or FEV1/FVC values, or steroid dependence/worsening with taper; CIU — baseline UAS7 or weekly itch/hive scores demonstrating severity and symptom duration (e.g., UAS7 ≥16, weekly itch ≥8); CRSwNP — baseline NPS and NCS with documentation of nasal polyp size and nasal congestion and confirmation by exam, CT, or endoscopy.

Include documentation of prior therapies (e.g., trials of H1 antihistamines for CIU; systemic corticosteroids or surgery for CRSwNP; inhaled corticosteroid + LABA and other controllers for asthma).
For re‑authorization, include chart notes showing clinical response (reduced exacerbations, oral steroid use, ER visits, itch severity, hives, decreased polyp size, improved NCS).

Note

Prior Authorization and Policy Change Notice

Policy change and history notice: updates to criteria, site‑of‑service review additions, and dosing/approval length clarifications become effective following provider notification timelines described in the policy history. Providers should review the policy history for effective dates and comment details when assessing prior authorization requirements.

Recent updates include: added site‑of‑service review, clarified FDA dosing adherence, changed initial CIU approval length to 6 months, and prohibitions on combination use with tezepelumab or dupilumab for specified indications.
Policy changes effective dates are listed in the History section (provider notification timelines noted).

Denial Risk

Combination Therapy and Site‑of‑Service Denials

Combination therapy and site‑of‑service denials: Xolair (omalizumab) will not be approved in combination with certain biologics for the same indication. Specifically, do not authorize concurrent use with tezepelumab for asthma, dupilumab for nasal polyps, or with other listed agents where contraindicated. Site‑of‑service medical necessity criteria can influence medical benefit reviews and may lead to denial if administered in a non‑medically necessary site.

Do not approve combination use of omalizumab with Tezspire (tezepelumab) for asthma.
Do not approve combination use of omalizumab with Dupixent (dupilumab) for CRSwNP.
Site‑of‑service reviews apply to injectable administration and may restrict coverage to medically necessary locations (office, infusion center, home infusion per criteria).